Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer
- 6 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (11), 2305-2317
- https://doi.org/10.1007/s00262-020-02609-5
Abstract
Background Perturbation of the CDK4/6 pathway is frequently observed in advanced bladder cancer. We investigated the potential of targeting this pathway alone or in combination with chemotherapy or immunotherapy as a therapeutic approach for the treatment of bladder cancer Methods The genetic alterations of the CDK4/6 pathway in bladder cancer were first analyzed with The Cancer Genome Atlas database and validated in our bladder cancer patient-derived tumor xenografts (PDXs). Bladder cancer cell lines and mice carrying PDXs with the CDK4/6 pathway perturbations were treated with a CDK4/6 inhibitor palbociclib to determine its anticancer activity and the underlying mechanisms. The combination index method was performed to assess palbociclib and gemcitabine drug–drug interactions. Syngeneic mouse bladder cancer model BBN963 was used to assess whether palbociclib could potentiate anti-PD1 immunotherapy. Results Of the 413 bladder cancer specimens, 79.2% harbored pertubations along the CDK4/6 pathway. Palbociclib induced G0/G1 cell cycle arrest but with minimal apoptosis in vitro. In mice carrying PDXs, palbociclib treatment reduced tumor growth and prolonged survival from 14 to 32 days compared to vehicle only controls (p = 0.0001). Palbociclib treatment was associated with a decrease in Rb phosphorylation in both cell lines and PDXs. Palbociclib and gemcitabine exhibited antagonistic cytotoxicity in vitro (CI > 3) and in vivo, but palbociclib significantly enhanced the treatment efficacy of anti-PD1 immunotherapy and induced CD8+ T lymphocyte infiltration in syngeneic mouse models. Conclusions The CDK4/6 pathway is feasible as a potential target for the treatment of bladder cancer, especially in combination with immunotherapy. A CDK4/6 inhibitor should not be combined with gemcitabine.Keywords
Funding Information
- National Cancer Institute (1 U54 CA233306, 1R01CA176803-01)
- U.S. Department of Veterans Affairs (1I01 BX003840)
This publication has 54 references indexed in Scilit:
- Emerging targeted agents in metastatic breast cancerNature Reviews Clinical Oncology, 2013
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaBlood, 2012
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer TherapyJNCI Journal of the National Cancer Institute, 2012
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBMProceedings of the National Academy of Sciences of the United States of America, 2010
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failureOncogene, 2010
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial XenograftsCancer Research, 2010
- D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significanceZeitschrift für Krebsforschung und Klinische Onkologie, 2010
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6Cell, 2004